Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | EVP AND GC | April 18, 2018 | April 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date April 18, 2018 · Filed April 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.98 · Expires 2028-04-17 | Direct | 28,125 |
Reported balance
After 2018-04-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-18 · Grant · Acquired 28,125 · Balance 28,125 F1: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option vest and become exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 9,800 | $30.46 | $298,473.70 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $30.60 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| December 27, 2016 Filed Dec 29, 2016 22:09 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,800 | $1.55 | $15,190.00 |
DisclosureSEC source: 0001415889-16-007636 · form4-12292016_021237.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · derivative · entry 5 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,878 Underlying: Common Stock · 10,000 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 10,000 | $30.00 | $300,001.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.01 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,000 | $1.55 | $15,500.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 22, 2016 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 8,635 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · derivative · entry 4 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,635 shares Expires 2018-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on October 22, 2009. The remaining shares vested and beaome exercisable thereafter in 36 equal monthly installments. Read SEC document |
| December 19, 2016 Filed Dec 22, 2016 00:03 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 8,635 | $1.64 | $14,161.40 |
DisclosureSEC source: 0001415889-16-007629 · form4-12212016_041225.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7 shares acquired on November 15, 2016 by Mr. Baity under the ACADIA Pharmaceuticals Employee Stock Purchase Plan. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (right to buy) · Derivative | 10,200 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · derivative · entry 3 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,878 Underlying: Common Stock · 10,200 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 10,200 | $30.07 | $306,687.48 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · nonDerivative · entry 2 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.17 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,200 | $1.55 | $15,810.00 |
DisclosureSEC source: 0001415889-16-007417 · form4-11142016_041144.xml · nonDerivative · entry 1 Baity Glenn · CIK 0001487100 · EVP AND GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.